These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34740747)

  • 21. Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial.
    Tarantini G; Mojoli M; Varbella F; Caporale R; Rigattieri S; Andò G; Cirillo P; Pierini S; Santarelli A; Sganzerla P; De Cesare N; Limbruno U; Lupi A; Ricci R; Cernetti C; Favero L; Saia F; Roncon L; Gasparetto V; Ferlini M; Ronco F; Ferri L; Trabattoni D; Russo A; Guiducci V; Penzo C; Tarantino F; Mauro C; Marchese A; Castiglioni B; La Manna A; Martinato M; Gregori D; Angiolillo DJ; Musumeci G
    Trials; 2020 Nov; 21(1):966. PubMed ID: 33234137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis.
    Wen M; Li Y; Qu X; Zhu Y; Tian L; Shen Z; Yang X; Shi X
    BMC Cardiovasc Disord; 2020 Oct; 20(1):430. PubMed ID: 33004000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
    Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Analysis from the Acute Coronary Syndrome Israeli Survey.
    Eliaz R; Mengesha B; Ovdat T; Iakobishvili Z; Hasdai D; Kheifets M; Klempfner R; Beigel R; Kalmanovich E; Alcalai R; Levi A
    Cardiology; 2022; 147(2):113-120. PubMed ID: 34808635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale and design of switch Swedeheart: A registry-based, stepped-wedge, cluster-randomized, open-label multicenter trial to compare prasugrel and ticagrelor for treatment of patients with acute coronary syndrome.
    Omerovic E; Erlinge D; Koul S; Frobert O; Andersson J; Ponten J; Björklund F; Kastberg R; Petzold M; Ljungman C; Bolin K; Redfors B
    Am Heart J; 2022 Sep; 251():70-77. PubMed ID: 35644221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of prescription rates and clinical outcomes in acute coronary syndrome patients who underwent percutaneous coronary intervention using different P2Y
    Choe JC; Cha KS; Ahn J; Park JS; Lee HW; Oh JH; Choi JH; Lee HC; Hong TJ; Jeong MH;
    Int J Cardiol; 2019 Jan; 274():21-26. PubMed ID: 30224257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.
    Serebruany VL; DiNicolantonio JJ
    Thromb Haemost; 2013 Jul; 110(1):5-10. PubMed ID: 23743577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
    Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
    Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial.
    Behnes M; Lahu S; Ndrepepa G; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Gewalt S; Witzenbichler B; Hochholzer W; Sibbing D; Cassese S; Angiolillo DJ; Hemetsberger R; Valina C; Müller A; Kufner S; Hamm CW; Xhepa E; Hapfelmeier A; Sager HB; Joner M; Fusaro M; Richardt G; Laugwitz KL; Neumann FJ; Schunkert H; Schüpke S; Kastrati A; Akin I
    Clin Res Cardiol; 2023 Apr; 112(4):518-528. PubMed ID: 35789430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prasugrel vs. ticagrelor after acute coronary syndrome: a critical appraisal of the ISAR-REACT 5 trial.
    Sulzgruber P; Niessner A
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):273-274. PubMed ID: 31865384
    [No Abstract]   [Full Text] [Related]  

  • 32. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention.
    Abraham NS; Yang EH; Noseworthy PA; Inselman J; Yao X; Herrin J; Sangaralingham LR; Ngufor C; Shah ND
    Aliment Pharmacol Ther; 2020 Aug; 52(4):646-654. PubMed ID: 32657466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial.
    Schulz S; Angiolillo DJ; Antoniucci D; Bernlochner I; Hamm C; Jaitner J; Laugwitz KL; Mayer K; von Merzljak B; Morath T; Neumann FJ; Richardt G; Ruf J; Schömig G; Schühlen H; Schunkert H; Kastrati A;
    J Cardiovasc Transl Res; 2014 Feb; 7(1):91-100. PubMed ID: 24371012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and pattern of urgent revascularization in acute coronary syndromes treated with ticagrelor or prasugrel.
    Aytekin A; Scalamogna M; Coughlan JJ; Lahu S; Ndrepepa G; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Witzenbichler B; Hochholzer W; Sibbing D; Angiolillo DJ; Hemetsberger R; Tölg R; Valina C; Müller A; Kufner S; Liebetrau C; Xhepa E; Hapfelmeier A; Sager HB; Joner M; Richardt G; Laugwitz KL; Neumann FJ; Schunkert H; Schüpke S; Kastrati A; Cassese S
    Clin Res Cardiol; 2024 Jul; 113(7):1060-1069. PubMed ID: 38740722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2Y
    Panzer B; Wadowski PP; Huber K; Panzer S; Gremmel T
    Diabet Med; 2022 Aug; 39(8):e14868. PubMed ID: 35514270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.
    Ariotti S; Ortega-Paz L; van Leeuwen M; Brugaletta S; Leonardi S; Akkerhuis KM; Rimoldi SF; Janssens G; Gianni U; van den Berge JC; Karagiannis A; Windecker S; Valgimigli M;
    JACC Cardiovasc Interv; 2018 Aug; 11(16):1576-1586. PubMed ID: 29805112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-Analysis Comparing P2Y
    Baldetti L; Melillo F; Moroni F; Gallone G; Pagnesi M; Venuti A; Beneduce A; Calvo F; Gramegna M; Godino C; D'Ascenzo F; De Ferrari GM; Capodanno D; Cappelletti AM
    Am J Cardiol; 2020 Jun; 125(12):1815-1822. PubMed ID: 32305225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial.
    Gewalt S; Lahu S; Ndrepepa G; Pellegrini C; Bernlochner I; Neumann FJ; Menichelli M; Morath T; Witzenbichler B; Wöhrle J; Hoppe K; Richardt G; Laugwitz KL; Schunkert H; Kastrati A; Schüpke S; Mayer K
    J Atheroscler Thromb; 2022 May; 29(5):747-761. PubMed ID: 33867409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis.
    Rodriguez AE; Rodriguez-Granillo AM; Ascarrunz SD; Peralta-Bazan F; Cho MY
    Curr Pharm Des; 2018; 24(4):465-477. PubMed ID: 29308737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
    Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM
    Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.